Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Sales (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Return on Sales for 5 consecutive years, with 0.12% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 13.0% year-over-year to 0.12%, compared with a TTM value of 0.1% through Dec 2025, up 19.0%, and an annual FY2025 reading of 0.1%, up 19.0% over the prior year.
  • Return on Sales was 0.12% for Q4 2025 at Kiniksa Pharmaceuticals International, up from 0.1% in the prior quarter.
  • Across five years, Return on Sales topped out at 2.26% in Q3 2022 and bottomed at 2.53% in Q3 2021.
  • Average Return on Sales over 5 years is 0.19%, with a median of 0.03% recorded in 2022.
  • The sharpest move saw Return on Sales surged 479bps in 2022, then tumbled -247bps in 2023.
  • Year by year, Return on Sales stood at 2.35% in 2021, then surged by 99bps to 0.03% in 2022, then soared by 3392bps to 0.99% in 2023, then crashed by -101bps to 0.01% in 2024, then soared by 2059bps to 0.12% in 2025.
  • Business Quant data shows Return on Sales for KNSA at 0.12% in Q4 2025, 0.1% in Q3 2025, and 0.11% in Q2 2025.